ABN AMRO Bank N.V. Has $248.20 Million Position in Stryker Corporation $SYK

ABN AMRO Bank N.V. boosted its position in Stryker Corporation (NYSE:SYK) by 40.4% during the third quarter, HoldingsChannel reports. The fund owned 673,936 shares of the medical technology company’s stock after buying an additional 193,782 shares during the quarter. Stryker comprises 2.4% of ABN AMRO Bank N.V.’s holdings, making the stock its 10th biggest position. ABN AMRO Bank N.V.’s holdings in Stryker were worth $248,203,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in SYK. Terra Alpha Investments LLC purchased a new position in Stryker in the 3rd quarter valued at approximately $1,216,000. Diversified Trust Co lifted its position in shares of Stryker by 45.6% during the third quarter. Diversified Trust Co now owns 12,445 shares of the medical technology company’s stock worth $4,601,000 after acquiring an additional 3,899 shares in the last quarter. SVB Wealth LLC bought a new position in shares of Stryker in the second quarter worth $4,785,000. AXQ Capital LP bought a new stake in shares of Stryker during the 2nd quarter valued at $567,000. Finally, National Pension Service lifted its holdings in Stryker by 2.4% during the 3rd quarter. National Pension Service now owns 683,867 shares of the medical technology company’s stock worth $252,805,000 after purchasing an additional 16,254 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

SYK opened at $360.19 on Thursday. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $137.74 billion, a P/E ratio of 42.88, a PEG ratio of 2.11 and a beta of 0.87. The stock has a 50-day moving average price of $358.84 and a 200-day moving average price of $371.11. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $404.87.

Stryker (NYSE:SYK) last released its earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, topping analysts’ consensus estimates of $4.40 by $0.07. The company had revenue of $7.17 billion during the quarter, compared to the consensus estimate of $7.12 billion. Stryker had a return on equity of 24.41% and a net margin of 12.92%.Stryker’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.01 EPS. Equities analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Tuesday, March 31st. Stryker’s payout ratio is presently 41.90%.

Analyst Upgrades and Downgrades

SYK has been the subject of a number of recent analyst reports. BTIG Research lifted their target price on Stryker from $410.00 to $412.00 and gave the company a “buy” rating in a report on Friday, January 30th. Evercore ISI set a $390.00 price objective on shares of Stryker in a research report on Monday, January 5th. Wall Street Zen lowered shares of Stryker from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. Needham & Company LLC increased their target price on shares of Stryker from $448.00 to $454.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. Finally, The Goldman Sachs Group set a $399.00 price target on shares of Stryker in a research report on Friday, January 9th. Twelve research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $426.56.

Insiders Place Their Bets

In related news, CFO Preston Wendell Wells sold 165 shares of the stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $365.88, for a total transaction of $60,370.20. Following the transaction, the chief financial officer owned 6,694 shares of the company’s stock, valued at approximately $2,449,200.72. This trade represents a 2.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO William E. Berry, Jr. sold 1,953 shares of Stryker stock in a transaction on Friday, November 14th. The stock was sold at an average price of $365.49, for a total transaction of $713,801.97. Following the completion of the transaction, the chief accounting officer owned 2,833 shares in the company, valued at approximately $1,035,433.17. The trade was a 40.81% decrease in their position. The SEC filing for this sale provides additional information. 5.90% of the stock is currently owned by corporate insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.